FDA Grants Priority Review to Savara's (SVRA) Molbreevi BLA
Savara Inc. (SVRA) has received FDA priority review for its Molbreevi Biologics License Application, a significant step for its drug targeting a rare lung condition, with a decision expected by August 22. Despite this positive development, the company currently reports zero revenue and negative EPS, indicating a pre-commercial stage with financial challenges. While institutional ownership is high, Savara's valuation metrics and recent insider selling suggest investors should approach with caution, weighing the drug's potential against inherent financial and sector-specific risks in biotechnology.
Savara (SVRA) Gains FDA Priority Review for Molbreevi BLA
Savara Inc. (SVRA) has received FDA Priority Review for its Biologics License Application (BLA) for Molbreevi, a therapeutic for autoimmune pulmonary alveolar proteinosis (PAP), with a target decision date of August 22, 2026. Despite this positive regulatory step, the company faces financial challenges, reporting zero revenue and ongoing losses, typical for biotech firms in the R&D phase. Investors are advised to consider the company's financial health, sector-specific risks, and market volatility alongside the promising BLA acceptance.
Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Savara Inc. announced that the FDA has filed its Biologics License Application for MOLBREEVI as a treatment for autoimmune Pulmonary Alveolar Proteinosis (PAP), granting it Priority Review with a target action date of August 22, 2026. The company also plans to submit Marketing Authorization Applications in Europe and the UK by the end of Q1 2026. MOLBREEVI has the potential to be the first and only approved therapy for autoimmune PAP in the U.S. and Europe, a rare lung disease characterized by abnormal surfactant build-up.
FDA fast-tracks potential first drug for rare lung disease
Savara Inc. announced that the FDA has granted Priority Review for its Biologics License Application (BLA) for MOLBREEVI, a potential treatment for autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP). The FDA set a PDUFA action date of August 22, 2026, signaling a potential first approved therapy for this rare lung disease in the U.S. and Europe. Savara plans to submit Marketing Authorization Applications for MOLBREEVI to European regulatory bodies by the end of Q1 2026.
Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Savara Inc. announced that the FDA has filed its Biologics License Application (BLA) for MOLBREEVI, a potential therapy for autoimmune Pulmonary Alveolar Proteinosis (PAP), and granted it Priority Review. The Prescription Drug User Fee Act (PDUFA) target action date is set for August 22, 2026. The company also plans to submit Marketing Authorization Applications (MAAs) for MOLBREEVI in Europe and the UK by the end of Q1 2026.
Savara Advances Pediatric aPAP Trial With Inhaled Molgramostim, Extending Its Rare Lung Disease Reach
Savara (SVRA) has provided an update on its ongoing Phase 3 clinical trial for inhaled molgramostim in pediatric patients with autoimmune Pulmonary Alveolar Proteinosis (aPAP). The study is open-label, interventional, and focuses on the efficacy and safety of the once-daily nebulized treatment, aiming to improve breathing and activity in children with this rare lung disease. This pediatric trial, which began in May 2024 and was last updated in February 2026, could significantly expand Savara's market reach in rare lung diseases if successful.
GSA Capital Partners LLP Has $1.33 Million Stock Holdings in Savara Inc. $SVRA
GSA Capital Partners LLP significantly reduced its stake in Savara Inc. (NASDAQ:SVRA) by 47.4% during Q3, selling 336,014 shares but still holding 372,449 shares valued at $1.33 million. Despite this reduction, other institutional investors like VR Adviser LLC, Nantahala Capital Management LLC, Emerald Advisers LLC, Geode Capital Management LLC, and Emerald Mutual Fund Advisers Trust increased their positions, bringing institutional ownership to 87.93%. Savara, a biopharmaceutical company focused on rare respiratory diseases, is trading around $5.59 with a "Moderate Buy" consensus rating and a target price of $8.86 from analysts.
Savara (SVRA) Is Up 7.1% After BLA Resubmission And Pricing Reveal For Lead aPAP Therapy - Has The Bull Case Changed?
Savara Inc. has seen a 7.1% increase in its stock after resubmitting its Biologics License Application (BLA) for its lead therapy, MOLBREEVI, and revealing a proposed annual price range of US$400,000–US$500,000. With US$264 million in capital and potential non-dilutive funding, the company is preparing for commercialization, focusing on a binary FDA decision despite significant regulatory and execution risks. The resubmission, supported by Fujifilm for manufacturing and agreed analytical protocols, sharpens the near-term catalyst for the company.
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA) announced the grant of inducement awards to a new employee, consisting of options to purchase 7,500 shares and restricted stock units (RSUs) for 7,500 shares. These awards were granted on February 10, 2026, under the Savara Inc. 2021 Inducement Equity Incentive Plan, to incentivize the new employee’s acceptance of employment. The options have an exercise price of $5.27 and a 10-year term, vesting quarterly, while the RSUs vest fully on the two-year anniversary of employment.
Savara, Inc. (SVRA) Stock Analysis: Exploring an 85% Potential Upside in the Biotech Sector
Savara, Inc. (SVRA) is a clinical-stage biopharmaceutical company focused on rare respiratory diseases, with its lead product molgramostim in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Analysts have issued unanimous "Buy" ratings and project an 85.46% potential upside to an average target price of $10.81, despite the company's current unprofitability and negative cash flow typical of biotech firms in R&D. The stock exhibits volatility but a long-term upward trend, with its RSI suggesting it may be nearing oversold territory, potentially signaling a buying opportunity for risk-tolerant investors.
Savara Insiders Added US$535.6k Of Stock To Their Holdings
Insiders at Savara Inc. (NASDAQ:SVRA) have been net buyers of the company's stock over the past year, with total purchases amounting to US$536k for 208.23k shares, despite some recent selling activity. While one independent director made a significant buy at a lower price, there has been recent selling by the same director. Despite recent selling, insiders still own about 2.0% of the company, suggesting some alignment with shareholder interests.
Savara Secures Path to $150M as FDA Decision Nears for Rare Lung Drug
Savara Inc. has amended its loan agreement with Hercules Capital, Inc., securing up to an additional $75 million, contingent on FDA approval of its rare lung disease drug, MOLBREEVI. This financing, combined with a previous royalty deal, brings Savara's potential non-dilutive capital to $150 million, providing strong financial backing for the drug's anticipated launch. MOLBREEVI, an investigational therapy for autoimmune pulmonary alveolar proteinosis, is awaiting a potential FDA approval in Q3 2026, with European filings also planned.
Savara Announces Participation in Upcoming February 2026 Investor Healthcare Conferences
Savara Inc., a biopharmaceutical company specializing in rare respiratory diseases, announced its participation in two investor healthcare conferences in February 2026. The management team will host one-on-one meetings and participate in fireside chats at the Guggenheim Emerging Outlook: Biotech Summit and the Oppenheimer 36th Annual Healthcare Life Sciences Conference. Webcasts and replays of these events will be available on the company's website.
Savara Announces Participation in Upcoming Investor Healthcare Conferences
Savara Inc. announced its management team will attend two investor healthcare conferences in February, hosting one-on-one meetings and participating in fireside chats. The events include the Guggenheim Emerging Outlook: Biotech Summit and the Oppenheimer 36th Annual Healthcare Life Sciences Conference. Webcasts of these sessions will be available on the company's corporate website.
Savara Inc. Launches Convenient DBS Test for Diagnosing Rare Lung Disease
Savara Inc. has introduced a new Dried Blood Spot (DBS) test to diagnose nontuberculous mycobacterial (NTM) lung disease more conveniently. The test, designed to improve early diagnosis of this rare and progressive condition, can be performed at home, eliminating the need for a clinic visit. This initiative aims to help a broader range of patients, including those with limited mobility, access timely diagnostic testing for NTM lung disease.
Expanded Hercules Credit Line Tied To MOLBREEVI Approval Could Be A Game Changer For Savara (SVRA)
Savara Inc. has amended its loan agreement with Hercules Capital, securing access to an additional US$75 million in debt financing, contingent on FDA approval of its MOLBREEVI therapy. This financing, along with upcoming regulatory filings in Europe and the U.K., aims to strengthen Savara's liquidity as it approaches crucial regulatory decisions and potential commercialization. While this improves the company's financial position, investors should still consider the inherent regulatory risks and current market valuations for Savara shares.
Savara grants equity awards to new hires as it advances rare lung drug
Savara, a clinical-stage biopharmaceutical company, announced it has granted equity awards to newly hired employees. These grants are part of the company's incentivization plan as it continues to advance its rare lung disease drug programs. The awards were made under an inducement plan outside of its stockholder-approved equity plan.
Hercules Capital Ties Savara Funding To FDA Milestone And Valuation Case
Hercules Capital has amended its loan agreement with Savara Inc., linking additional funding to FDA approval of Savara's lead therapy. This strategy highlights Hercules Capital's approach to biotech financing, with investors encouraged to monitor how such contingent structures influence its risk profile and deal pipeline. The deal also presents a valuation case for Hercules Capital, noting its shares trade below analyst targets and estimated fair value.
Savara Grants Equity Awards to New Hires as It Advances Rare Lung Drug
Savara Inc. (Nasdaq: SVRA) has awarded equity grants to two new employees to strengthen its workforce as it progresses with the late-stage development of MOLBREEVI, a treatment for a rare respiratory disease. These inducement awards, comprising stock options and restricted stock units, align with Nasdaq listing rules and are part of the company's strategy to invest in talent for its clinical and operational efforts in rare disease development.
How Investors May Respond To Savara (SVRA) Adding Approval-Linked Hercules Credit To Its Liquidity Toolkit
Savara Inc. has secured an amendment to its loan agreement with Hercules Capital Inc., providing access to an additional US$75 million in debt financing contingent on FDA approval of MOLBREEVI. This move, combined with existing royalty funding, strengthens Savara's liquidity to support a potential launch without immediate reliance on equity markets. However, the company still faces regulatory hurdles and legal risks, and its valuation remains a subject of diverse opinion among investors.
Savara Ekes up on Deal with Hercules
Savara Inc. announced an amendment to its loan and security agreement with Hercules Capital, Inc., which will provide up to an additional $75 million upon FDA approval of its investigational therapy, MOLBREEVI. This agreement, combined with previous financing, ensures Savara will have approximately $150 million in non-dilutive capital to support MOLBREEVI's potential launch. The company resubmitted its BLA for MOLBREEVI in December 2025 and plans to file MAAs in Europe and the U.K. by the end of Q1 2026.
Savara Ekes up on Deal with Hercules
Savara Inc. announced an amendment to its loan agreement with Hercules Capital, Inc., making an additional $75 million available upon FDA approval of their investigational therapy, MOLBREEVI. This agreement, combined with previous royalty financing, provides Savara with approximately $150 million in non-dilutive capital to support MOLBREEVI's potential launch later in 2026. The company's shares saw a slight increase following the announcement.
Savara Enters New Material Definitive Agreement and Obligation
Savara Inc. reported on January 27, 2026, that it has entered a material definitive agreement, as confirmed by CFO Dave Lowrance. While the specific implications of this agreement are not detailed, it signals a potentially significant development for the company's corporate and financial future. An analyst has a Hold rating on SVRA stock with a $6.00 price target, and TipRanks' AI Analyst, Spark, rates SVRA as Neutral due to weak financial performance and challenging valuation, despite potential positive corporate events related to funding and regulatory outcomes.
Savara secures additional $75m in debt financing for potential drug launch
Savara Inc. has secured an additional $75 million in debt financing from Hercules Capital, bringing its total non-dilutive capital for drug launch activities to $150 million. This funding is contingent upon FDA approval of MOLBREEVI, Savara's investigational therapy for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). The company resubmitted the Biologics License Application for MOLBREEVI in December 2025 and anticipates potential approval in Q3 2026.
Savara (SVRA) Faces Class Action Lawsuit Over Shareholder Losses
Savara (SVRA) is facing a class action lawsuit filed by Bragar Eagel & Squire, P.C. due to alleged shareholder losses. The lawsuit stems from the FDA's rejection of Savara's MOLBREEVI Biologics License Application, which caused a significant stock price drop and substantial losses for investors. The complaint suggests Savara failed to disclose critical information about the BLA, impacting its capital raising.
SAVARA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is
Bragar Eagel & Squire, P.C. is investigating Savara, Inc. (NASDAQ:SVRA) on behalf of long-term stockholders due to potential breaches of fiduciary duties. This follows a class action complaint filed after Savara received a refusal to file letter from the FDA for its MOLBREEVI BLA, leading to a significant drop in its stock price. The firm encourages investors who held shares between March 7, 2024, and May 23, 2025, to contact them to discuss their legal options.
Savara, Inc. (SVRA) Stock Analysis: Exploring a 67% Potential Upside in Rare Respiratory Disease Biotech
Savara, Inc. (SVRA) is a clinical-stage biopharmaceutical company focused on rare respiratory diseases, with its lead product candidate, molgramostim, in Phase 3 trials. Analysts project a potential upside of 67.38%, with an average target price of $10.81, driven by strong market sentiment and the potential success of its drug development. Despite current unprofitability, typical for clinical-stage biotechs, the company's strategic focus and analyst confidence suggest significant future growth potential for risk-tolerant investors.
Rare lung drug nears FDA decision as PANTHERx, Savara seal US deal
Savara has partnered with PANTHERx Rare for the exclusive distribution of its rare lung disease drug, molgramostim, in the U.S. if it receives FDA approval. The decision for molgramostim, intended for autoimmune pulmonary alveolar proteinosis (aPAP), is expected by June 28, 2024. This collaboration aims to ensure patient access to the first potential treatment for aPAP.
Rare Lung Drug Nears FDA Decision as PANTHERx, Savara Seal U.S. Deal
PANTHERx Rare Pharmacy and Savara Inc. have entered an exclusive U.S. distribution agreement for MOLBREEVI, an investigational inhaled therapy for autoimmune pulmonary alveolar proteinosis. Savara submitted a biologics license application to the FDA in December 2025, requesting Priority Review, with PANTHERx set to manage nationwide dispensing and patient support if approved. This partnership aims to ensure timely access and comprehensive care for patients with this rare lung disease.
Savara Secures $75 Million Royalty Deal to Back Potential MOLBREEVI Launch
Savara, a clinical-stage biopharmaceutical company, has secured a non-dilutive royalty monetization agreement worth up to $75 million with HealthCare Royalty Partners. This deal provides funding to support the potential launch of MOLBREEVI (aeroVANC) for non-tuberculous mycobacteria (NTM) lung disease, pending successful Phase 3 clinical trials and regulatory approval. The initial $50 million upfront payment will strengthen Savara's balance sheet and extend its cash runway.
Savara Secures $75 Million Royalty Deal to Back Potential MOLBREEVI Launch
Savara has secured a $75 million royalty financing agreement with Ligature Partners and HealthCare Royalty Partners. This funding is intended to support the potential commercial launch of MOLBREEVI for autoimmune PAP, if approved. The agreement highlights financial preparation for bringing this rare disease treatment to market.
What Savara (SVRA)'s Exclusive PANTHERx MOLBREEVI Distribution Deal Means For Shareholders
Savara Inc. has announced an exclusive U.S. distribution agreement with PANTHERx Rare Pharmacy for MOLBREEVI, following its Biologics License Application submission to the FDA. This partnership aims to provide a clear commercialization path for MOLBREEVI, including patient support, strengthening Savara's investment narrative, though the company still faces challenges with cash burn and ongoing losses. The agreement is a positive step towards launch readiness, contingent on FDA approval, with two fair value estimates for Savara ranging widely, underscoring the divergence of opinions on its prospects.
What Savara (SVRA)'s Exclusive PANTHERx MOLBREEVI Distribution Deal Means For Shareholders
Savara (SVRA) has secured an exclusive U.S. distribution agreement with PANTHERx Rare Pharmacy for MOLBREEVI, following its Biologics License Application submission to the FDA. This partnership aims to strengthen Savara's commercialization path and patient access for MOLBREEVI, leveraging PANTHERx's specialized rare-disease focus. While this deal adds clarity to launch execution, Savara faces ongoing challenges including cash burn, recent shareholder dilution, and the binary risk associated with FDA approval.
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA) has announced the grant of inducement awards to two new employees. These awards, consisting of options to purchase 17,500 shares of common stock and 12,500 restricted stock units (RSUs), were granted on January 15, 2026, under the Savara Inc. 2021 Inducement Equity Incentive Plan, to incentivize their employment. The options have an exercise price of $5.88 per share and vest quarterly, while the RSUs vest fully on the two-year anniversary of employment.
Savara Reports 2024 Financial Results and Provides Updates on MOLBREEVI Progress
Savara has reported its 2024 financial results and provided updates on the progress of its drug candidate, MOLBREEVI. The company is advancing its clinical development, and these results offer insight into its financial health and operational performance related to the drug's journey through regulatory processes and market preparation.
Lobbying Update: $30,000 of SAVARA INC. lobbying was just disclosed
SAVARA INC. (SVRA) recently disclosed $30,000 in lobbying expenditures for Q4 2025, focusing on prescription drug payment reform, supply chain issues, and Medicare/Medicaid. The article also details recent insider trading activity, institutional investor movements (both additions and reductions in holdings), and a summary of recent "Buy" and "Overweight" analyst ratings with a median price target of $10.0.
With 37% stake, Savara Inc. (NASDAQ:SVRA) seems to have captured institutional investors' interest
Savara Inc. (NASDAQ:SVRA) is drawing significant attention from institutional investors, who collectively own 37% of the company's shares. This substantial institutional stake suggests a degree of credibility among professional investors, though it also implies that the stock price could be susceptible to their trading decisions. Key shareholders include New Enterprise Associates, Inc., and hedge funds, alongside a meaningful stake held by company insiders.
Savara Inc. (NASDAQ:SVRA) Given Average Rating of "Moderate Buy" by Analysts
Savara Inc. (NASDAQ:SVRA) has received a consensus "Moderate Buy" rating from analysts, with an average one-year price target of $9.13. The company's primary clinical catalyst is its lead candidate, Molgradex, currently under regulatory review for autoimmune pulmonary alveolar proteinosis (PAP). Despite being unprofitable, Savara has seen increased institutional investment, with shares opening at $5.81 and a market cap of approximately $1.18 billion.
Savara Inc. Grants Inducement Awards to New Employees with Stock Options & RSUs
Savara Inc. announced it granted inducement awards consisting of stock options and restricted stock units (RSUs) to three new employees. These awards were approved by the Compensation Committee of Savara's Board of Directors and are intended to comply with Nasdaq Listing Rule 5635(c)(4). The grants vest over several years, contingent on continued employment.
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*
PANTHERx Rare has been selected by Savara Inc. as the exclusive U.S. specialty pharmacy for MOLBREEVI, an investigational medicine for autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP). Savara submitted the MOLBREEVI Biologics License Application (BLA) in December 2025 to the FDA, requesting Priority Review. If approved, PANTHERx will handle dispensing and distribution, providing patient and prescriber support through its RxARECARE® model.
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI
PANTHERx® Rare Pharmacy has been selected by Savara Inc. as the exclusive U.S. specialty pharmacy for MOLBREEVI, an investigational medicine for autoimmune Pulmonary Alveolar Proteinosis (PAP). Savara submitted a Biologics License Application (BLA) for MOLBREEVI to the FDA in December 2025. This partnership aims to provide comprehensive patient and prescriber support services, ensuring timely access and adherence to therapy if MOLBREEVI receives approval.
Savara Highlights Autoimmune PAP Burden in Updated Presentation
Savara (SVRA) has updated its corporate presentation to emphasize the high burden and unmet medical needs associated with autoimmune pulmonary alveolar proteinosis (PAP), a rare respiratory disease. The update reinforces the strategic rationale for its investigational product, MOLBREEVI, and solidifies the company's focus on rare respiratory conditions. TipRanks' AI Analyst, Spark, rates SVRA as Neutral due to weak financial performance despite some technical support.
The Bull Case For Savara (SVRA) Could Change Following Exclusive MOLBREEVI Distribution Deal With PANTHERx
Savara (SVRA) has entered into an exclusive U.S. distribution agreement with PANTHERx Rare Pharmacy for its drug MOLBREEVI, which is awaiting FDA approval for autoimmune PAP treatment. This deal provides Savara with a ready-made commercial channel and patient support infrastructure, mitigating commercialization risks. While this strengthens the investment narrative by focusing on regulatory approval, risks such as equity dilution, high valuation, and continued cash burn remain.
The Bull Case For Savara (SVRA) Could Change Following Exclusive MOLBREEVI Distribution Deal With PANTHERx
Savara Inc. has entered into an exclusive U.S. distribution agreement with PANTHERx Rare Pharmacy for its drug MOLBREEVI, which is awaiting FDA approval for autoimmune PAP. This partnership could streamline Savara's commercialization efforts by providing a ready-built distribution and patient support network. While the deal clarifies the commercial pathway, risks such as equity dilution and high valuation persist, and the company's investment case heavily relies on the FDA's regulatory decision.
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*
PANTHERx® Rare Pharmacy has been chosen by Savara Inc. as the exclusive U.S. specialty pharmacy for MOLBREEVI, an investigational medicine for autoimmune Pulmonary Alveolar Proteinosis (PAP). Savara submitted a Biologics License Application for MOLBREEVI in December 2025, and if approved, PANTHERx will manage its distribution and provide specialized patient and prescriber support services. This partnership aims to ensure timely access and comprehensive care for patients with this rare lung disease.
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*
Savara Inc. has chosen PANTHERx Rare Pharmacy as the exclusive U.S. specialty pharmacy for MOLBREEVI, an investigational medicine for autoimmune Pulmonary Alveolar Proteinosis (PAP). Savara submitted the Biologics License Application (BLA) for MOLBREEVI to the FDA in December 2025. This partnership aims to provide comprehensive patient support services and ensure timely access to the potential treatment for individuals with this rare lung disease.
FDA clock restarts: Savara refiles MOLBREEVI for rare lung disease
Savara has refiled its New Drug Application (NDA) for MOLBREEVI, a treatment for nontuberculous mycobacterial (NTM) lung disease that is refractory to standard therapy. The FDA accepted the application for review, classifying it as a Class 2 resubmission, which resets the "FDA clock" for the regulatory process. If approved, MOLBREEVI would be the first inhaled drug specifically for NTM lung disease, addressing a significant unmet medical need.
FDA Clock Restarts: Savara Refiles MOLBREEVI for Rare Lung Disease
Savara Inc. has resubmitted its biologics license application for MOLBREEVI to the FDA, targeting autoimmune pulmonary alveolar proteinosis, a rare lung disease. The resubmission includes a request for Priority Review and names FUJIFILM Biotechnologies as the drug substance manufacturer. MOLBREEVI has already received Fast Track, Breakthrough Therapy, Orphan Drug, Innovation Passport, and Promising Innovative Medicine designations, highlighting its potential clinical importance in addressing an unmet medical need.
Savara (NASDAQ:SVRA) Shares Down 5.1% - Should You Sell?
Savara (NASDAQ:SVRA) shares fell 5.1% to $6.0070 on Tuesday, with trading volume significantly lower than average. Despite the dip, analyst sentiment remains largely positive, with an average rating of "Moderate Buy" and a target price of $9.13, supported by strong liquidity and low leverage. The company's lead drug, Molgradex, is under regulatory review, and institutional investors hold approximately 88% of the stock.
Savara Heads to JPMorgan Conference as Investors Watch Rare Lung Drug
Savara Inc. (Nasdaq: SVRA) will present its leading program, MOLBREEVI, at the 44th Annual J.P. Morgan Healthcare Conference. The company is developing MOLBREEVI, a treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease, which is currently in Phase 3 clinical trials. This conference appearance offers Savara a platform to engage with investors and partners, highlighting its progress in rare respiratory diseases.
